Current Opinion in Clinical Nutrition and Metabolic Care. 13(6):729–736, NOVEMBER 2010

DOI: 10.1097/MCO.0b013e32833ef291

,  

PMID: 20823772

Issn Print: 1363-1950

Publication Date: November 2010


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome?

Jean-Louis Beaudeux;Valérie Nivet-antoine;Philippe Giral;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Purpose of reviewThe metabolic syndrome is associated with increased risk for development of both cardiovascular disease and type 2 diabetes in humans. Because experimental data and clinical experience have shown that metabolic syndrome and caloric restriction have, at least partly, opposite pathophysiological pathways, the activation of sirtuins may constitute a pharmacological approach to treat metabolic syndrome. Resveratrol is a polyphenol produced by plants that has multiple beneficial activities similar to those associated with caloric restriction.Recent findingsThrough its regulatory action of both AMP kinase and the sirtuin sirtuin-1, resveratrol is a natural sirtuin activator that certainly will be the head of a new pharmacological family of drugs targeted on sirtuin-1 activity exacerbation in order to treat/protect from obesity and diabetes, and thus metabolic syndrome.SummaryThis review discusses the therapeutic use of resveratrol and sirtuin activators in the context of insulin resistance and obesity, the two main features of metabolic syndrome.

Related Topics

    Related Articles

        loading  Loading Related Articles